By Dr. Drew Edwards, EdD | March 22, 2026
"I don't understand it. I'm not weak. I just can't stop."
I've heard that sentence — or something close to it — thousands of times across three decades of clinical practice. From physicians. From parents. From college students who never imagined they'd end up in my office. They come carrying enormous shame, convinced their inability to quit is a moral failing. Conventional treatment has done nothing to correct that belief. In many cases, it deepens it.
A study published today in Nature Mental Health may finally shift that. Researchers at Rutgers Health analyzed genetic data from more than 2.2 million people across alcohol, tobacco, cannabis, and opioid use disorders. Their finding is as clear as it is consequential: the primary driver of addiction risk isn't drug-specific. It's how the brain is wired for reward processing and impulse control. Most of the genetic risk for developing a substance use disorder runs through what the researchers call a broad "externalizing" pathway — genes governing how the brain weighs consequences, regulates impulses, and processes reward. Not which substance someone uses. Not even whether they use at all. The architecture of the brain itself.
The brain that was already running on empty
What the Rutgers team documented at scale is what my colleagues and I have described clinically for years as Reward Deficiency Syndrome — a neurobiological condition in which the brain's dopamine reward circuitry is chronically underperforming. Addiction is not a choice problem. It's a brain problem. The externalizing pathway the researchers identified is shared across addiction, ADHD, and risk-taking behavior — not because these are the same condition, but because they share the same upstream deficit: a reward system that isn't getting enough signal.
Dopamine mediates everything we experience as satisfying. Motivation. Pleasure. The feeling that something was worth doing. When someone carries genetic variants that reduce dopamine tone in the nucleus accumbens and prefrontal cortex, the brain is perpetually searching for something to close that gap. A drink closes it. Opioids slam it shut. The relief is real, immediate, and neurochemically logical. That's the part conventional treatment never explains to patients — and it's the part that destroys them with shame when the relief stops working and they can't quit. Two point two million people's genetic data now confirms what patients already know in their bodies: something in the brain was different before the first drink.
Recovery requires more than abstinence
This is where treatment consistently fails. If Addictive Disease begins with a neurobiological deficit — and we now have genome-wide data from over two million individuals to say it does — then treatment must address that deficit directly. Abstinence is necessary. It isn't sufficient. A depleted reward system doesn't replenish itself simply because the substance is removed. For many patients in early recovery, the absence of the drug reveals the original deficit more starkly than before: flat affect, anhedonia, inability to feel pleasure from anything. This is the window when relapse is most likely, and it's a window the treatment industry largely ignores.
Dopamine, serotonin, and GABA are not conjured from good intentions. The brain synthesizes them from raw materials — amino acid precursors, B-complex vitamins, omega-3 fatty acids, magnesium. When those raw materials are scarce, neurotransmitter production suffers. People in active addiction and early recovery are almost universally depleted in these nutrients: poor diet, chronic stress, disrupted sleep, and the metabolic demands of detoxification compound the deficit. We've compiled over 400 peer-reviewed studies on this relationship at our Evidence page, and the evidence is consistent — targeted nutritional support can play a meaningful role in supporting the brain's natural neurotransmitter production. You can read more about the neuronutrient approach in our earlier post, Healing the Addicted Brain With Neuronutrients, and on how the gut microbiome affects brain chemistry in The Gut Microbiome and Brain Health.
Giving the brain what it needs to rebuild
For anyone navigating addiction recovery — or supporting someone who is — this study is not just academic validation. It's a reason to stop blaming the person and start looking at what the brain actually needs. Treatment must address neurobiological deficits and craving. Anything less is a waste of time.
Several targeted nutrients can support the brain's natural reward and neurotransmitter systems as part of a comprehensive recovery approach. 5-HTP ($29.49) provides a direct precursor to serotonin — a neurotransmitter that plays a central role in mood regulation and reward. When serotonin levels are supported, the brain's overall reward circuitry functions more stably. The Complete Multivitamin ($25.90) delivers the B-complex vitamins that serve as essential cofactors in dopamine and serotonin synthesis — nutrients commonly depleted in anyone under sustained physical or emotional stress. Magnesium Glycinate ($26.90) supports GABA receptor function and the nervous system's ability to modulate stress responses, which is often critically compromised during recovery. And Brain Focus Nootropic Formula ($29.81) provides a blend of neuronutrients designed to support cognitive function and executive performance — exactly the capacities the externalizing pathway governs.
None of these replace medical treatment, therapy, or recovery support. They are tools. But they address something that conventional addiction medicine has been slow to take seriously: the brain's raw material needs. The 2026 Nature Mental Health study tells us that the vulnerable brain was wired differently from the start. It makes sense — neurobiologically and clinically — to give that brain what it needs to function as well as it can.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Frequently asked questions
Is addiction really genetic?
Research strongly suggests genetics play a major role in addiction vulnerability. A 2026 study in Nature Mental Health analyzing over 2.2 million individuals found that most genetic addiction risk operates through brain systems governing reward processing and impulse control — not through drug-specific pathways.
What is Reward Deficiency Syndrome?
Reward Deficiency Syndrome (RDS) is a condition characterized by a clinically significant deficiency of dopamine in the brain's reward circuitry. People with RDS may be more susceptible to addiction, ADHD, depression, and other reward-related disorders because the brain's natural reward signaling is underperforming.
Can supplements support addiction recovery?
Nutritional supplements can support the brain's natural neurotransmitter production as part of a comprehensive recovery approach. Nutrients like amino acid precursors (such as 5-HTP), B vitamins, magnesium, and omega-3 fatty acids provide the raw materials the brain uses to synthesize dopamine, serotonin, and GABA. They are not a substitute for medical treatment.
Why does relapse happen so often in addiction recovery?
Relapse frequently occurs because the underlying neurobiological deficit — low dopamine tone in the reward circuitry — remains unaddressed after abstinence. When the substance is removed, the original dopamine deficiency is exposed, creating anhedonia and cravings. Comprehensive recovery addresses both abstinence and neurobiological restoration.
What is the externalizing pathway in addiction?
The externalizing pathway refers to a shared genetic and neurological pathway involving brain systems for reward processing, self-regulation, and impulse control. Research shows this broad pathway accounts for most of the genetic risk across alcohol, tobacco, cannabis, and opioid use disorders — suggesting addiction vulnerability is rooted in brain architecture, not individual weakness.
Sources:
Nature Mental Health, March 2026 | Rutgers Research | Evidence Page
